The efficacy of binutuzumab and belimumab [humanized monoclonal antibody against B-cell activating factor (BAFF)] in lupus nephritis, another disease mediated in part by autoreactive B cells, and CD19 CAR T cells in treatment-refractory SLE are also promising alternative B cell-depleting therapies, which require further evaluation in PMN (160–163). Here, TNFSF13B is linked to systemic lupus erythematosus.